Trump Reg Freeze Could Put Controversial FDA Draft Guidances On Hold
January 24, 2017
President Donald Trump put heads of executive departments and agencies on notice that no new rules or guidances should be sent to the Office of the Federal Register (OFR) until a Trump-appointed or designated agency head reviews and approves them, potentially putting controversial FDA draft guidances and notices on such hot-button issues as off-label use, new dietary ingredients, compounding and biosimilars on hold. The order allows for new regulations under certain health, safety, financial, or national security matters in emergency...
Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting as the Trump administration and congressional Republicans take on the dismantling and replacement of the Affordable Care Act.